Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Inclusion Criteria: * Patients with hematologic malignancies undergoing first HID allo-HSCT * Age 18 to 65 years old with ECOG performance status 0-2 * Received myeloablative conditioning regimens * Sign informed consent form, have the ability to comply with study and follow-up procedures Exclusion Criteria: * Received PBSCs as only grafts * Acute leukemia transformed from a myeloproliferative tumor * Cardiac dysfunction (particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy) * Respiratory failure ( PaO2 ≤60mmHg) * Hepatic abnormalities (total bilirubin ≥3 mg/dL, aminotransferase \>2 times the upper limit of normal) * Renal dysfunction (creatinine clearance rate \< 30 mL/min) * ECOG performance status 3, 4 or 5 * With any conditions not suitable for the trial (investigators' decision)